SIAXI: Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions: results of a Phase III, placebo-controlled, randomised, doubleblind study

被引：0
|
作者：
Csikos, J. [1 ]
Blitzer, A. [2 ]
Friedman, A. [3 ]
Michel, O. [4 ,5 ]
Flatau-Baque, B. [6 ]
Jost, W.
机构：
[1] Merz Pharmaceut, Frankfurt, Germany
[2] Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 630 W 168th St, New York, NY 10032 USA
[3] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[4] Med Univ Warsaw, Dept Neurol, Fac Hlth Sci, Warsaw, Poland
[5] Univ Hosp Brussels, Otorhinolaryngol, Brussels, Belgium
[6] Parkinson Klin Wolfach, Wolfach, Germany
来源：
INTERNATIONAL JOURNAL OF STROKE | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [1] SIAXI: Efficacy and safety of Xeomin (incobotulinumtoxinA) for the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions: Results of a Phase III, placebo-controlled, randomized, double-blind study
    Jost, Wolfgang
    Friedman, Andrzej
    Michel, Olaf
    Flatau-Baque, Birgit
    Csikos, Janos
    Blitzer, Andrew
    [J]. NEUROLOGY, 2018, 90
  • [2] SIAXI: INCOBOTULINUMTOXINA FOR SIALORRHEA IN PARKINSON'S DISEASE, STROKE, AND OTHER ETIOLOGIES-PHASE 3 RESULTS
    Jost, Wolfgang
    Friedman, Andrzej
    Michel, Olaf
    Flatau-Baque, Birgit
    Hast, Michael
    Csikos, Janos
    Blitzer, Andrew
    [J]. MUSCLE & NERVE, 2018, 58 : S57 - S57
  • [3] SIAXI: IncobotulinumtoxinA for sialorrhea in Parkinson's disease, stroke, and other etiologies-Phase 3 Results
    Blitzer, Andrew
    Friedman, Andrzej
    Michel, Olaf
    Flatau-Baque, Birgit
    Csikos, Janos
    Jost, Wolfgang
    [J]. NEUROLOGY, 2018, 90
  • [4] MYSTICOL: A controlled study of Myobloc in the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions
    Hubble, J.
    Isaacson, S.
    Severt, L.
    Clinch, T.
    [J]. MOVEMENT DISORDERS, 2016, 31 (09) : E3 - E3
  • [5] Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhea in Parkinson's disease and other neurologic conditions
    Pagan, F.
    Jost, W.
    Friedman, A.
    Michel, O.
    Oehlwein, C.
    Slawek, J.
    Bogucki, A.
    Ochudlo, S.
    Banach, M.
    Flatau-Baque, B.
    Csikos, J.
    Blitzer, A.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S754 - S754
  • [6] IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson's disease and other neurological conditions
    Jost, W.
    Pagan, F.
    [J]. MOVEMENT DISORDERS, 2022, 37 : S453 - S454
  • [7] MYSTICOL: A multisite, double-blind, randomized, placebo-controlled trial of rimabotulinumtoxinB for the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions
    Isaacson, Stuart
    Jackson, Carlayne
    Molho, Eric
    Trosch, Richard
    Ondo, William
    Clinch, Thomas
    [J]. NEUROLOGY, 2017, 88
  • [8] EFFICACY AND SAFETY OF INCOBOTULINUMTOXINA FOR THE TREATMENT OF SIALORRHEA: RESULTS OF THE MAIN PHASE OF A PHASE 3 STUDY
    Jost, Wolfgang H.
    Michel, Olaf
    Oehlwein, Christian
    Slawek, Jaroslaw
    Bogucki, Andrzej
    Ochudlo, Stanislaw
    Banach, Marta
    Pagan, Fernando
    Flatau-Baque, Birgit
    Csikos, Janos
    Blitzer, Andrew
    [J]. TOXICON, 2018, 156 : S53 - S53
  • [9] Efficacy of incobotulinumtoxinA in patients with sialorrhea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson's disease (mROMP): Results of the SIAXI study
    Jost, W.
    Friedman, A.
    Michel, O.
    Oehlwein, C.
    Slawek, J.
    Bogucki, A.
    Ochudlo, S.
    Banach, M.
    Pagan, F.
    Flatau-Baque, B.
    Csikos, J.
    Blitzer, A.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S713 - S714
  • [10] Efficacy and safety of incobotulinumtoxinA in the combined treatment of upper facial lines: Results of the first prospective randomised, double-blind, placebo-controlled, multicentre phase III study
    Rzany, Berthold
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB16 - AB16
12345